There is on-going development of generic EU CTD Dossier of Lercanidipine, filmcoated tablets, 10/20 mg.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Lercanidipine is a calcium channel blocker of the dihydropyridine class.
It is sold under various commercial names including Zanidip.